ACT PIOGLITAZONE 30 MG — DIN 02302888
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is ACT PIOGLITAZONE?
ACT PIOGLITAZONE 30 MG contains PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02302888, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Dec-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACT PIOGLITAZONE used for?
Teva - Pioglitazone (pioglitazone hydrochloride) is indicated as monotherapy in patients not controlled by diet and exercise alone, to decrease blood glucose levels in patients with type 2 diabetes mellitus (non - insulin dependent diabetes mellitus, NIDDM). Teva - Pioglitazone is indicated for use in combination with a sulfonylurea or metformin when diet and exercise plus the single agent do not result in adequate glycemic control.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Pioglitazone cost around the world?
Pioglitazone is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 3 | 55 | USD███.██ |
| Czechia | max producer price (ex-factory) | 8 | 33 | CZK███.██ |
| Australia | ex-manufacturer | 3 | 18 | AUD███.██ |
| Saudi Arabia | public | 18 | 18 | SAR███.██ |
| Italy | prezzo al pubblico (classe A) | 6 | 15 | EUR███.██ |
| South Africa | single exit price | 9 | 10 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 7 | 7 | EUR███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
173 pack listings across 70 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Pioglitazone pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Pioglitazone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
23 holders have a Canadian DIN containing Pioglitazone, across 77 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 6 | 3 | ACT PIOGLITAZONE, TEVA-PIOGLITAZONE | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 3 | 3 | ACH-PIOGLITAZONE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 3 | JAMP PIOGLITAZONE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 3 | 3 | MINT-PIOGLITAZONE | Sourceable in Canada |
| ACCEL PHARMA INC | 6 | 0 | ACCEL PIOGLITAZONE, PIOGLITAZONE | No marketed DIN |
| RANBAXY PHARMACEUTICALS CANADA INC. | 6 | 0 | RAN-PIOGLITAZONE | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 3 | 0 | MYLAN-PIOGLITAZONE | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-PIOGLITAZONE | No marketed DIN |
| PHARMEL INC | 3 | 0 | PHL-PIOGLITAZONE | No marketed DIN |
| PRO DOC LIMITEE | 3 | 0 | PRO-PIOGLITAZONE | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 3 | 0 | RATIO-PIOGLITAZONE | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 3 | 0 | SANDOZ PIOGLITAZONE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Pioglitazone |
|---|---|
| ATC code | A10BG03 |
| AHFS class | 68:20.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02302888 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2302888 |
| Brand name | ACT PIOGLITAZONE |
| Generic / active ingredient | PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | A10BG03 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10BG |
| Current status | MARKETED |
| Status date | 12-Dec-2025 |
| Original market date | 2007-12-05 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 77 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-PIOGLITAZONE | 15 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02391600 |
| ACH-PIOGLITAZONE | 30 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02339587 |
| ACH-PIOGLITAZONE | 45 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02339595 |
| ACT PIOGLITAZONE | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02302861 |
| ACT PIOGLITAZONE | 45 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02302896 |
| JAMP PIOGLITAZONE | 45 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02365537 |
| JAMP PIOGLITAZONE | 30 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02365529 |
| JAMP PIOGLITAZONE | 15 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02397307 |
| MINT-PIOGLITAZONE | 15 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02326477 |
| MINT-PIOGLITAZONE | 30 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02326485 |
2 · Same class — other molecules in ATC A10BG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pioglitazone | ACCEL PIOGLITAZONE · ACH-PIOGLITAZONE · ACT PIOGLITAZONE · ACTOS · AG-PIOGLITAZONE · APO-PIOGLITAZONE · AURO-PIOGLITAZONE · AVA-PIOGLITAZONE · DOM-PIOGLITAZONE · JAMP PIOGLITAZONE · MINT-PIOGLITAZONE · MYLAN-PIOGLITAZONE · PHL-PIOGLITAZONE · PIOGLITAZONE · PIOGLITAZONE HCL · PMS-PIOGLITAZONE · PRO-PIOGLITAZONE · RAN-PIOGLITAZONE · RATIO-PIOGLITAZONE · SANDOZ PIOGLITAZONE · TEVA-PIOGLITAZONE · TORRENT-PIOGLITAZONE · VAN-PIOGLITAZONE · ZYM-PIOGLITAZONE | 77 | 12 | Yes |
| Rosiglitazone | AVANDIA · DOM-ROSIGLITAZONE · MYLAN-ROSIGLITAZONE · PHL-ROSIGLITAZONE · PMS-ROSIGLITAZONE · ROSIGLITAZONE · TEVA-ROSIGLITAZONE | 21 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10BD | Combinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · Metformin And Dapagliflozin · Metformin And Empagliflozin · Metformin And Linagliptin · Metformin And Rosiglitazone · Metformin And Saxagliptin · Metformin And Sitagliptin · Pioglitazone And Alogliptin · Saxagliptin And Dapagliflozin | 123 | 67 |
| A10BH | Alogliptin · Linagliptin · Saxagliptin · Sitagliptin | 91 | 63 |
| A10BA | Metformin | 122 | 45 |
| A10BK | Canagliflozin · Dapagliflozin · Empagliflozin · Ertugliflozin | 42 | 30 |
| A10BX | Nateglinide · Repaglinide · Tirzepatide | 54 | 30 |
| A10BB | Acetohexamide · Chlorpropamide · Glibenclamide · Gliclazide · Glimepiride · Tolbutamide | 112 | 23 |
| A10BJ | Albiglutide · Dulaglutide · Exenatide · Liraglutide · Lixisenatide · Semaglutide | 34 | 13 |
| A10BF | Acarbose | 6 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACT PIOGLITAZONE called?
The same molecule, Pioglitazone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| NOVAPIO | Latin | Czechia |
| Actos | Latin | Australia, Czechia, South Africa |
| ARX-PIOGLITAZONE | Latin | Australia |
| PIOGLITAZONE ACCORD | Latin | Czechia |
| Vexazone | Latin | Australia |
| PIOGLITAZON ACTAVIS | Latin | Czechia |
| PIOGLITAZON VIATRIS | Latin | Czechia |
| DUETACT | Latin | Bahrain |
| PIOGLITAZON MYLAN | Latin | Czechia |
| ACTOSMET | Latin | Bahrain |
| COMPETACT | Latin | Czechia |
| Glitamomet | Latin | Saudi Arabia |
| NOVAPIO PLUS | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.